Results from the DAPA-HF trial demonstrate that dapagliflozin therapy is associated with lower risk of worsening heart failure or cardiovascular death than placebo, regardless of the presence or absence of diabetes.

中文翻译：

---

Dapagliflozin-在寻找治疗HFrEF药物方面的突破。

DAPA-HF试验的结果表明，无论是否存在糖尿病，达格列净治疗与心脏衰竭或心血管死亡恶化的风险均低于安慰剂。